[PDF][PDF] Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
JC Bendell, J Rodon, HA Burris, M De Jonge… - J Clin …, 2012 - researchgate.net
J Clin Oncol, 2012•researchgate.net
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With
Advanced Solid Tumors Page 1 Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class
I PI3K Inhibitor, in Patients With Advanced Solid Tumors Johanna C. Bendell, Jordi Rodon,
Howard A. Burris, Maja de Jonge, Jaap Verweij, Diana Birle, David Demanse, Stefan S. De
Buck, Qinhua C. Ru, Malte Peters, Michael Goldbrunner, and José Baselga See accompanying
article doi: 10.1200/JCO.2011.38.7167 Johanna C. Bendell and Howard A. Burris, Sarah …
Advanced Solid Tumors Page 1 Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class
I PI3K Inhibitor, in Patients With Advanced Solid Tumors Johanna C. Bendell, Jordi Rodon,
Howard A. Burris, Maja de Jonge, Jaap Verweij, Diana Birle, David Demanse, Stefan S. De
Buck, Qinhua C. Ru, Malte Peters, Michael Goldbrunner, and José Baselga See accompanying
article doi: 10.1200/JCO.2011.38.7167 Johanna C. Bendell and Howard A. Burris, Sarah …
Purpose
This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activity, pharmacokinetics (PK), and pharmacodynamics of BKM120, a potent and highly specific oral pan-Class I PI3K inhibitor.
researchgate.net